ESMO Breast 2022 | The clinical impact of gene expression assays on early luminal breast cancer

Nadia Harbeck, MD, PhD, Ludwig Maximilians University – Grosshadern, Munich, Germany, talks on the clinical impact of gene expression assays on luminal early breast cancer. Such tests can aid in deciding against chemotherapy in node-negative premenopausal woman and node-negative and node-positive postmenopausal woman with up to 3 lymph nodes. In node-positive premenopausal woman, however, the addition of an endocrine response assessment provides a more accurate recommendation for chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.